These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22453559)

  • 41. [HIV/HCV double infection: combination is a clear therapy option].
    Reich B
    Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
    [No Abstract]   [Full Text] [Related]  

  • 42. [Hepatitis C].
    Pache I; Gonvers JJ
    Rev Med Suisse Romande; 2002 Oct; 122(10):507-12. PubMed ID: 12494784
    [No Abstract]   [Full Text] [Related]  

  • 43. Management of hepatitis C.
    Smith C
    Minn Med; 2003 Jun; 86(6):53-6. PubMed ID: 12834215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe renal impairment during triple therapy with telaprevir.
    Carrier P; Chambaraud T; Vong C; Guillaudeau A; Debette-Gratien M; Jacques J; Legros R; Sautereau D; Essig M; Loustaud-Ratti V
    Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):e69-71. PubMed ID: 24461554
    [No Abstract]   [Full Text] [Related]  

  • 46. [Drug therapy of hepatitis B and C].
    Färkkilä M
    Duodecim; 2003; 119(6):519-29. PubMed ID: 12708339
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of hepatitis C in children.
    Aziz S
    J Coll Physicians Surg Pak; 2005 Jun; 15(6):317-8. PubMed ID: 15924831
    [No Abstract]   [Full Text] [Related]  

  • 48. The basics of new treatment for chronic hepatitis C.
    Lemon MD; Meade F
    S D J Med; 2001 Aug; 54(8):303-4. PubMed ID: 11523457
    [No Abstract]   [Full Text] [Related]  

  • 49. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
    Foruny JR; Bárcena R; Moreno A; Blázquez J; Manzano R; Gil-Grande LA; Moreno A; Nuño J
    Transplantation; 2006 Jul; 82(2):289-90. PubMed ID: 16858295
    [No Abstract]   [Full Text] [Related]  

  • 50. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
    Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
    J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment strategies of acute and chronic hepatitis C].
    Gładysz A; Inglot M
    Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
    O'Leary JG; McKenna GJ; Klintmalm GB; Davis GL
    Liver Transpl; 2013 Apr; 19(4):463-5. PubMed ID: 23408534
    [No Abstract]   [Full Text] [Related]  

  • 53. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 54. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C (chronic).
    Mohsen A; Norris S
    Clin Evid; 2006 Jun; (15):1061-72. PubMed ID: 16973044
    [No Abstract]   [Full Text] [Related]  

  • 56. [Hepatitis? What is it?].
    Hernández ML
    Sidahora; 2002; (4):11-3. PubMed ID: 12703473
    [No Abstract]   [Full Text] [Related]  

  • 57. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY; Ferrante SA; Elbasha EH; Hsu TY
    Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin.
    Paul S; Javed U; Tevendale R; Lanford J; Liu R
    AIDS; 2007 Mar; 21(6):784-5. PubMed ID: 17413709
    [No Abstract]   [Full Text] [Related]  

  • 60. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.